Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL).

Palamarchuk A, Yan PS, Zanesi N, Wang L, Rodrigues B, Murphy M, Balatti V, Bottoni A, Nazaryan N, Alder H, Rassenti L, Kipps TJ, Freitas M, Croce CM, Pekarsky Y.

Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2555-60. doi: 10.1073/pnas.1200003109. Epub 2012 Jan 30.

2.

Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL.

Pekarsky Y, Palamarchuk A, Maximov V, Efanov A, Nazaryan N, Santanam U, Rassenti L, Kipps T, Croce CM.

Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19643-8. doi: 10.1073/pnas.0810965105. Epub 2008 Dec 8.

3.

CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation.

Efanov A, Zanesi N, Nazaryan N, Santanam U, Palamarchuk A, Croce CM, Pekarsky Y.

Leukemia. 2010 May;24(5):970-5. doi: 10.1038/leu.2010.46. Epub 2010 Apr 1.

4.

Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181.

Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, Volinia S, Alder H, Liu CG, Rassenti L, Calin GA, Hagan JP, Kipps T, Croce CM.

Cancer Res. 2006 Dec 15;66(24):11590-3.

5.

Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice.

Zanesi N, Aqeilan R, Drusco A, Kaou M, Sevignani C, Costinean S, Bortesi L, La Rocca G, Koldovsky P, Volinia S, Mancini R, Calin G, Scott CP, Pekarsky Y, Croce CM.

Cancer Res. 2006 Jan 15;66(2):915-20.

6.

Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.

DiLillo DJ, Weinberg JB, Yoshizaki A, Horikawa M, Bryant JM, Iwata Y, Matsushita T, Matta KM, Chen Y, Venturi GM, Russo G, Gockerman JP, Moore JO, Diehl LF, Volkheimer AD, Friedman DR, Lanasa MC, Hall RP, Tedder TF.

Leukemia. 2013 Jan;27(1):170-82. doi: 10.1038/leu.2012.165. Epub 2012 Jul 13.

7.

TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia.

Balatti V, Rizzotto L, Miller C, Palamarchuk A, Fadda P, Pandolfo R, Rassenti LZ, Hertlein E, Ruppert AS, Lozanski A, Lozanski G, Kipps TJ, Byrd JC, Croce CM, Pekarsky Y.

Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2169-74. doi: 10.1073/pnas.1500010112. Epub 2015 Feb 2.

8.

Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression.

Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R, Russo G, Hardy RR, Croce CM.

Proc Natl Acad Sci U S A. 2002 May 14;99(10):6955-60.

9.

ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.

Widhopf GF 2nd, Cui B, Ghia EM, Chen L, Messer K, Shen Z, Briggs SP, Croce CM, Kipps TJ.

Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):793-8. doi: 10.1073/pnas.1308374111. Epub 2013 Dec 30.

10.

Absence of caveolin-1 leads to delayed development of chronic lymphocytic leukemia in Eμ-TCL1 mouse model.

Shukla A, Cutucache CE, Sutton GL, Pitner MA, Rai K, Rai S, Opavsky R, Swanson PC, Joshi SS.

Exp Hematol. 2016 Jan;44(1):30-7.e1. doi: 10.1016/j.exphem.2015.09.005. Epub 2015 Oct 3.

PMID:
26435347
11.

B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia.

Yan XJ, Albesiano E, Zanesi N, Yancopoulos S, Sawyer A, Romano E, Petlickovski A, Efremov DG, Croce CM, Chiorazzi N.

Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11713-8. Epub 2006 Jul 24.

12.

Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression.

Enzler T, Kater AP, Zhang W, Widhopf GF 2nd, Chuang HY, Lee J, Avery E, Croce CM, Karin M, Kipps TJ.

Blood. 2009 Nov 12;114(20):4469-76. doi: 10.1182/blood-2009-06-230169. Epub 2009 Sep 15. Erratum in: Blood. 2010 Jul 29;116(4):671.

13.

Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia.

Sivina M, Hartmann E, Vasyutina E, Boucas JM, Breuer A, Keating MJ, Wierda WG, Rosenwald A, Herling M, Burger JA.

Leukemia. 2012 Aug;26(8):1812-20. doi: 10.1038/leu.2012.63. Epub 2012 Mar 5.

PMID:
22460735
14.

miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.

Bresin A, Callegari E, D'Abundo L, Cattani C, Bassi C, Zagatti B, Narducci MG, Caprini E, Pekarsky Y, Croce CM, Sabbioni S, Russo G, Negrini M.

Oncotarget. 2015 Aug 14;6(23):19807-18.

15.

PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.

Holler C, Piñón JD, Denk U, Heyder C, Hofbauer S, Greil R, Egle A.

Blood. 2009 Mar 19;113(12):2791-4. doi: 10.1182/blood-2008-06-160713. Epub 2009 Jan 23.

16.

Tcl1 interacts with Atm and enhances NF-κB activation in hematologic malignancies.

Gaudio E, Spizzo R, Paduano F, Luo Z, Efanov A, Palamarchuk A, Leber AS, Kaou M, Zanesi N, Bottoni A, Costinean S, Rassenti LZ, Nakamura T, Kipps TJ, Aqeilan RI, Pekarsky Y, Trapasso F, Croce CM.

Blood. 2012 Jan 5;119(1):180-7. doi: 10.1182/blood-2011-08-374561. Epub 2011 Nov 7.

17.

High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia.

Herling M, Patel KA, Weit N, Lilienthal N, Hallek M, Keating MJ, Jones D.

Blood. 2009 Nov 19;114(21):4675-86. doi: 10.1182/blood-2009-03-208256. Epub 2009 Sep 21.

18.

Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice.

Kriss CL, Pinilla-Ibarz JA, Mailloux AW, Powers JJ, Tang CH, Kang CW, Zanesi N, Epling-Burnette PK, Sotomayor EM, Croce CM, Del Valle JR, Hu CC.

Blood. 2012 Aug 2;120(5):1027-38. doi: 10.1182/blood-2011-11-394346. Epub 2012 Jun 12.

19.

Accelerated progression of chronic lymphocytic leukemia in Eμ-TCL1 mice expressing catalytically inactive RAG1.

Nganga VK, Palmer VL, Naushad H, Kassmeier MD, Anderson DK, Perry GA, Schabla NM, Swanson PC.

Blood. 2013 May 9;121(19):3855-66, S1-16. doi: 10.1182/blood-2012-08-446732. Epub 2013 Mar 15.

20.

TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state.

Herling M, Patel KA, Khalili J, Schlette E, Kobayashi R, Medeiros LJ, Jones D.

Leukemia. 2006 Feb;20(2):280-5.

PMID:
16341048

Supplemental Content

Support Center